Neuralstem's ALS therapy works in 'subset' of patients
This article was originally published in Scrip
Executive Summary
Neuralstem is moving forward with development of its spinal cord-derived stem cell treatment for patients with amyotrophic lateral sclerosis (ALS) following mostly positive Phase II results for the product.